NASDAQ:EPZM - Epizyme Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.56 0.00 (0.00 %) (As of 01/21/2019 03:01 AM ET)Previous Close$9.56Today's Range$9.37 - $9.7852-Week Range$5.14 - $21.40Volume542,308 shsAverage Volume1.19 million shsMarket Capitalization$756.85 millionP/E Ratio-4.39Dividend YieldN/ABeta2.04 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Eisai Co. Ltd.; Lymphoma Study Association; and Boehringer Ingelheim. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Receive EPZM News and Ratings via Email Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPZM Previous Symbol CUSIPN/A Webwww.epizyme.com Phone617-229-5872Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48Price-To-Earnings Trailing P/E Ratio-4.39 Forward P/E Ratio-4.93 P/E GrowthN/A Sales & Book Value Annual Sales$10 million Price / Sales75.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.40 per share Price / Book2.81Profitability EPS (Most Recent Fiscal Year)($2.18) Net Income$-134,300,000.00 Net MarginsN/A Return on Equity-64.87% Return on Assets-55.18%Miscellaneous Employees131 Outstanding Shares79,170,000Market Cap$756.85 million OptionableOptionable Epizyme (NASDAQ:EPZM) Frequently Asked Questions What is Epizyme's stock symbol? Epizyme trades on the NASDAQ under the ticker symbol "EPZM." How were Epizyme's earnings last quarter? Epizyme Inc (NASDAQ:EPZM) issued its earnings results on Friday, November, 2nd. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.07. View Epizyme's Earnings History. When is Epizyme's next earnings date? Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Epizyme. What price target have analysts set for EPZM? 9 equities research analysts have issued 1 year price objectives for Epizyme's stock. Their forecasts range from $11.00 to $27.00. On average, they expect Epizyme's stock price to reach $20.50 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View Analyst Price Targets for Epizyme. What is the consensus analysts' recommendation for Epizyme? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme. Has Epizyme been receiving favorable news coverage? Media coverage about EPZM stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Epizyme earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Epizyme's key competitors? Some companies that are related to Epizyme include HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD) and Supernus Pharmaceuticals (SUPN). Who are Epizyme's key executives? Epizyme's management team includes the folowing people: Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 52)Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory BoardDr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory BoardMs. Suzanne Fleming, Principal Financial Officer, Sr. VP of Fin., Treasurer & Principal Accounting Officer (Age 58) Who are Epizyme's major shareholders? Epizyme's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (8.69%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme. Which institutional investors are buying Epizyme stock? EPZM stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Epizyme. How do I buy shares of Epizyme? Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Epizyme's stock price today? One share of EPZM stock can currently be purchased for approximately $9.56. How big of a company is Epizyme? Epizyme has a market capitalization of $756.85 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe. What is Epizyme's official website? The official website for Epizyme is http://www.epizyme.com. How can I contact Epizyme? Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected] MarketBeat Community Rating for Epizyme (NASDAQ EPZM)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 358 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 626MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?